These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29512735)

  • 1. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
    Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 4. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
    Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
    Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
    Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
    Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
    Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
    An YY; Kim SH; Kang BJ
    World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.
    Lee HS; Ko BS; Ahn SH; Son BH; Lee JW; Kim HJ; Yu JH; Kim SB; Jung KH; Ahn JH; Cha JH; Kim HH; Lee HJ; Song IH; Gong G; Park SH; Lee JJ; Moon DH
    Breast Cancer Res Treat; 2014 May; 145(1):91-100. PubMed ID: 24671359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
    Veys I; Pop CF; Barbieux R; Moreau M; Noterman D; De Neubourg F; Nogaret JM; Liberale G; Larsimont D; Bourgeois P
    PLoS One; 2018; 13(5):e0197857. PubMed ID: 29799849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
    Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
    Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study.
    Wahner-Roedler DL; Boughey JC; Hruska CB; Chen B; Rhodes DJ; Tortorelli CL; Maxwell RW; Cha SS; O'Connor MK
    Clin Nucl Med; 2012 Apr; 37(4):344-50. PubMed ID: 22391702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Nakashima K; Uematsu T; Harada TL; Takahashi K; Nishimura S; Tadokoro Y; Hayashi T; Watanabe J; Sugino T; Notsu A
    Breast Cancer; 2021 Sep; 28(5):1120-1130. PubMed ID: 33837896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
    Collarino A; Valdés Olmos RA; van Berkel LGAJ; Neijenhuis PA; Wijers LMH; Smit F; de Geus-Oei LF; Pereira Arias-Bouda LM
    Breast Cancer Res Treat; 2018 Jun; 169(3):513-522. PubMed ID: 29435855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
    Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
    Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.